Differences

This shows you the differences between two versions of the page.

--- covid-19_vaccines:research_and_development [2022/08/13 17:06]
pamela
+++ covid-19_vaccines:research_and_development [2022/08/13 17:13] (current)
pamela [NIH Funding SARS - Coronavirus Vaccine Development]
@@ Line 11: / Line 11: @@
 ==== NIH Funding SARS - Coronavirus Vaccine Development ====
-Human Antibodies and Targeted Vaccines Against SARS-CoV
+Coronavirus vaccine development
+Project Number1ZIAAI005125-02
+Contact PI/Project LeaderGRAHAM, BARNEY
+Awardee OrganizationNATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
+When the MERS CoV outbreak raised global health concerns, we initiated a program to develop a candidate vaccine. Starting from [[:Spike glycoprotein]] (S) sequences, we developed an immunization strategy consisting of a full-length S DNA prime and a S1 subunit protein boost that elicited high titers of neutralizing antibodies against eight different MERS-CoV strains. Immune sera contained potent neutralizing antibodies targeting the receptor binding domain (RBD), non-RBD portions of S1, and the S2 subunit.
+From the immunized mice we produced a panel of hybridomas and produced [[:monoclonal antibodies]] from which a variety with high neutralizing activity were selected for further characterization. The atomic structure of a monoclonal antibodyD12in complex with the RBD revealed two distinct mechanisms by which they block binding to the MERS-CoV receptor, DPP4. In addition, immunogenicity was measured in nonhuman primates. Thus, vaccine immunogens designed from S sequences induced a diverse repertoire of neutralizing antibodies, demonstrating an efficient approach to [[:vaccine design]] that may be applicable to other emerging viruses. Structural studies were also initiated with the spike glycoprotein of the HKU1 beta-coronavirus, to explore structure and for receptor discovery. Human airway epithelial cell culture system was established to initiate entry and pathogenesis studies of HKU1.  ((https://web.archive.org/web/20220813141434/https://reporter.nih.gov/search/Bfy82rGilEC37c9JBlm_dA/project-details/9161779))
+
+Human Antibodies and Targeted Vaccines Against SARS-CoV
 Project Number5U01AI061318-05
 Contact PI/Project Leader MARASCO, WAYNE A.